marked.bio

KRAS G12C inhibitor · small molecule

HRS-7058

3 active trials, targeting KRAS G12C. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 3 3 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of HRS-7058.

  1. Jiangsu Hengrui 3

Trials

3 of 3 trials shown

  1. A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment

    Not yet recruiting Phase 3 Jiangsu Hengrui Started 2026Primary completion 2028-05 NCT07601048

    HRS-7058fulzerasibgarsorasibglecirasib

    …enter Phase III Trial of HRS-7058 Versus the Investigator-Selected KRAS G12C Inhibitor in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Stand…

    KRAS G12CKRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment

  2. An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

    Recruiting Phase 2 Jiangsu Hengrui Started 2026Primary completion 2028-12 NCT07589569

    HRS-7058

    …y of HRS-7058 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Harboring KRAS G12C Mutations Who Have Failed Prior Systemic Therapy.

    KRAS G12CPancreatic Cancer

  3. A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

    Recruiting Phase 1 Jiangsu Hengrui Started 2024Primary completion 2026-06 NCT06383871

    HRS-7058

    …inetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C Mutation

    KRAS G12CAdvanced Malignant Tumour